Status:
NOT_YET_RECRUITING
Validation of Betalactam ML Prediction Models - TDMAide
Lead Sponsor:
University Hospital, Ghent
Collaborating Sponsors:
Research Foundation Flanders
Imec
Conditions:
Infections
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The goal of this study is to learn about the real wold behavior of developed machine learning models that predict the plasma concentration of piperacillin-tazobactam and meropenem in critically ill pa...
Eligibility Criteria
Inclusion
- Patients
- Admission to the ICU.
- Age above 18 years old.
- Treatment with piperacillin-tazobactam or meropenem for less than 48 hours.
Exclusion
- Pregnant or lactating patients.
- Limitation of therapy beyond "Do not resuscitate".
- Expected demise within 48 hours after inclusion.
- Haemoglobin \< 7 g/dL.
- Previous inclusion in this study for a treatment course with the same antimicrobial.
- Consultants and physicians in training
- Inclusion Criteria:
- Consultant or physician in training working in the ICU.
Key Trial Info
Start Date :
September 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06026852
Start Date
September 26 2024
End Date
May 31 2025
Last Update
June 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Ghent
Ghent, Belgium, 9000